FindTrial
Sign In

IPI-549

DRUG2 trials

Sponsors

Arcus Biosciences, Inc., Assuntina G. Sacco, MD

Conditions

HPV-Related CarcinomaHPV-Related MalignancyHPV-Related Squamous Cell CarcinomaHead and Neck CancerHead and Neck Cancer Stage IIIHead and Neck Cancer Stage IVHead and Neck CarcinomaHead and Neck Squamous Cell Carcinoma

Phase 1

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
CompletedNCT03719326
Arcus Biosciences, Inc.Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
Start: 2018-10-15End: 2021-07-02Updated: 2024-05-24

Phase 2

IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
CompletedNCT03795610
Assuntina G. Sacco, MDHead and Neck Cancer, Head and Neck Cancer Stage III, Head and Neck Cancer Stage IV +5
Start: 2020-03-06End: 2023-08-24Updated: 2025-07-25

Related Papers

GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.
2021-08-0136 citations
Abstract PS12-12: Efficacy and safety of AB928 plus pegylated liposomal doxorubicin (PLD) with or without IPI-549 in participants with metastatic ovarian and triple negative breast cancer
Cancer Research2021-02-154 citations
AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.
Journal of Clinical Oncology2019-05-2032 citations